https://www.selleckchem.com/pr....oducts/pyrintegrin.h
60 (CI 0.50-0.7 and 0.61 (CI 0.51-0.71) (P=0.4. Median follow-up was 32months (IQR 31-33), during which 99 patients (32%) had a cardiovascular event and 110 (36%) died. A doubling of MR-proANP concentration was associated with a hazard ratio (HR) of 1.6 (CI 1.3-1.9) before and 1.7 (CI 1.4-2. after dialysis for mortality and a HR of 1.5 (CI 1.2-1.9) before and 1.4 (CI 1.2-1.7) after dialysis for cardiovascular events (all P0.001). The MR-proANP concentration is elevated among patients undergoing hemodialysis and decreases d
Curtir
Comentario
Compartilhar
